Stockholm - Delayed Quote SEK

Diamyd Medical AB (publ) (DMYD-B.ST)

9.52

0.00

(0.00%)

At close: 5:29:44 PM GMT+2

Diamyd Medical Announces Positive Interim Analysis Results for Phase 3 Trial in Type 1 Diabetes

Diamyd Medical today announced a successful interim analysis (non-futility test) for its ongoing precision medicine Phase 3 DIAGNODE-3 trial. The interim analysis, reviewed by an independent Data Safety Monitoring Board (DSMB), resulted in a favorable recommendation to continue the trial without any modifications.

PR Newswire 9 months ago

DMYD-B.ST
0.00%
Diamyd Medical receives second U.S. FDA Fast Track designation for Diamyd® - for the prevention of Type 1 Diabetes

Diamyd Medical announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Diamyd® (rhGAD65/alum) to treat Type 1 Diabetes in pediatric patients with Stage 1 or Stage 2 Type 1 Diabetes carrying the genotype HLA DR3-DQ2. Earlier this year, Diamyd® received Fast Track designation for the treatment of individuals with Stage 3 Type 1 Diabetes carrying the HLA DR3-DQ2 genotype. The FDA grants Fast Track designation to facilitate the development and expedite

PR Newswire 9 months ago

DMYD-B.ST
0.00%

Performance Overview

Return	DMYD-B.ST	OMX Stockholm 30 Index (^OMX)
YTD	-42.09%	+3.22%
1-Year	-21.06%	-2.63%
3-Year	-44.25%	+28.53%